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Information extractionThe management of drug–drug interactions (DDIs) is a critical issue resulting from the overwhelming
amount of information available on them. Natural Language Processing (NLP) techniques can provide
an interesting way to reduce the time spent by healthcare professionals on reviewing biomedical litera-
ture. However, NLP techniques rely mostly on the availability of the annotated corpora. While there are
several annotated corpora with biological entities and their relationships, there is a lack of corpora anno-
tated with pharmacological substances and DDIs. Moreover, other works in this ﬁeld have focused in
pharmacokinetic (PK) DDIs only, but not in pharmacodynamic (PD) DDIs. To address this problem, we
have created a manually annotated corpus consisting of 792 texts selected from the DrugBank database
and other 233 Medline abstracts. This ﬁned-grained corpus has been annotated with a total of 18,502
pharmacological substances and 5028 DDIs, including both PK as well as PD interactions. The quality
and consistency of the annotation process has been ensured through the creation of annotation guide-
lines and has been evaluated by the measurement of the inter-annotator agreement between two anno-
tators. The agreement was almost perfect (Kappa up to 0.96 and generally over 0.80), except for the DDIs
in the MedLine database (0.55–0.72). The DDI corpus has been used in the SemEval 2013 DDIExtraction
challenge as a gold standard for the evaluation of information extraction techniques applied to the rec-
ognition of pharmacological substances and the detection of DDIs from biomedical texts. DDIExtraction
2013 has attracted wide attention with a total of 14 teams from 7 different countries. For the task of rec-
ognition and classiﬁcation of pharmacological names, the best system achieved an F1 of 71.5%, while, for
the detection and classiﬁcation of DDIs, the best result was F1 of 65.1%. These results show that the cor-
pus has enough quality to be used for training and testing NLP techniques applied to the ﬁeld of Pharma-
covigilance. The DDI corpus and the annotation guidelines are free for use for academic research and are
available at http://labda.inf.uc3m.es/ddicorpus.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Motivated by the information explosion in Biomedicine, over
the last decade there has been a surge of interest in using Natural
Language Processing (NLP) techniques to retrieve and extract infor-
mation from biomedical texts [1]. Most of these techniques rely
heavily on annotated corpora to learn models that can be used to
extract information from raw text. Annotated corpora are valuable
resources as they provide a gold standard data for the repeatable
automatic training and evaluation of NLP techniques [2]. Most re-
cent research has centered on biological entities and their relation-
ships (such as gene and protein interactions) mainly as a result ofthe availability of annotated corpora in the biological domain (see
Section 2).
Other biomedical domains such as Pharmacovigilance (the sci-
ence concerned with the prevention of adverse drug reactions)
can beneﬁt from NLP techniques. This is the case of drug–drug
interactions (DDIs), which are a common adverse drug reactions
having a signiﬁcant impact on patient safety and healthcare costs
[3,4]. Although there is a large quantity of drug databases and
semi-structured resources (such as DrugBank [5], Stockley [6] or
Drug Interactions Facts [7], among others) to assist healthcare pro-
fessionals avoid DDIs, the quality of these databases is very uneven
and the consistency of their content is limited, so it is very difﬁcult
to assign a real clinical signiﬁcance to each interaction [8,9]. On the
other hand, despite the availability of these databases, a large
amount of the most current and valuable information is unstruc-
tured, written in natural language and hidden in published articles,
scientiﬁc journals, books and technical reports [3]. Only in the
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searches is increased between 10,000 and 20,000 articles per week
[10]. Therefore, researchers and healthcare professionals must re-
view a large number of drug safety reports as well as publications
in the ﬁelds of medicine and pharmacology in order to be kept up-
to-date with everything published about DDIs. Several published
drug safety studies have shown that DDIs may be detected too late,
when millions of patients have already been exposed [11]. There-
fore, the management of DDIs is a critical issue as a result of the
overwhelming amount of information available on them [12].
Thus, the development of automatic methods for collecting, main-
taining and interpreting the information about drugs is crucial to
achieving a real improvement in the early detection of DDIs.
In this paper, we describe the construction of a gold standard
corpus, called the DDI corpus, which is annotated with pharmaco-
logical substances as well as the interactions between them. The
DDI corpus is the ﬁrst corpus which includes pharmacodynamic
(PD) and pharmacokinetic (PK) DDIs. A PD DDI occurs when the
pharmacological effects of one drug are modiﬁed by the presence
of another drug, while a PK DDI is the result from the interference
of drug absorption, distribution, metabolism and/or elimination of
a drug by another drug. While there are several annotated corpora
with biological entities and their relationships (see Section 2), the
shortage of annotated corpora for DDI extraction is the main bot-
tleneck in the development of NLP systems for this area of
Pharmacovigilance.
The DDI corpus has been developed for the DDI Extraction 2013
challenge (http://www.cs.york.ac.uk/semeval-2013/task9/), whose
main goal is to provide a common framework for the evaluation of
information extraction techniques applied to the recognition of
pharmacological substances and the detection of DDIs from bio-
medical texts. For this purpose, two substasks have been proposed:
the recognition and classiﬁcation of drug names and the extraction
and classiﬁcation of their interactions. A detailed description of the
task, the participant teams, the results and the evaluation metrics
can be found in [13].Table 1
Size of the biomedical corpora annotated with drugs.
Corpus Type of document Size Drugs DDIs
EU-ADR MedLine abstract 300 1753
ADE MedLine sentences 4272 5063
ITI TXM Full articles 400 18,000
PK-DDI Drug package inserts 68 3986 592
PK MedLine abstract 428 1333
CLEF Patient records 150 1972. Related work
The identiﬁcation of drug names is a preliminary and crucial
step in many text mining tasks such as the detection of the out-
break of diseases [14], the extraction of medication-related infor-
mation [15], the detection of adverse-drug events [16] or the
extraction of relationships such as drug-disease [17], drug-gene
interactions [18], DDIs [19], among many others. In fact, several
corpora have been built for these purposes in recent years. Here,
we review the main corpora annotated with drug entities, giving
a special focus on those corpora that also contain DDIs.
Since each corpus has been developed for a speciﬁc task, the
deﬁnition of the drug entity varies signiﬁcantly from corpus to cor-
pus. Thus, for example, in Clinical E-Science Framework (CLEF) [20]
and BioText [21] corpora, drug names and therapeutic devices or
interventions are annotated with the same entity type. Other cor-
pora such as ADE (Adverse Drug Effect) [22], EU-ADR (Exploring
and Understanding Adverse Drug Reactions) [2] or ITI TXM (Tissue
Expressions and Protein–Protein Interactions) [23] use a single en-
tity type to annotate both drugs and chemicals, while the BioCaster
[14] corpus distinguishes between substances for the treatment of
diseases and chemicals not intended for therapeutic purposes. Cor-
pora such as PK-DDI (Pharmacokinetic drug–drug interaction) [24]
or that developed by Rubrichi and Quaglini [25] propose a more
ﬁne-grained classiﬁcation of pharmacological substances. The
annotation schema of the PK-DDI corpus describes three types of
entity to annotate pharmacological substances: ACTIVE INGREDI-
ENT, DRUG PRODUCT and METABOLITE. Similarly, Rubrichi et al.,propose three different entity types: ACTIVE DRUG INGREDIENT,
DRUG or DRUG CLASS. In the PK corpus [26], drug names and
metabolites are automatically annotated using a dictionary from
the DrugBank database, and later manually reviewed.
To the best of our knowledge, the only two works that have ad-
dressed the annotation of DDIs are the PK-DDI corpus and the PK
corpus. These are the closest works to ours, but differ from it in
the scope of the annotated DDIs. While these corpora only contain
PK DDIs, the DDI corpus also includes PD DDIs.
As regards the type of document, almost all of the aforemen-
tioned corpora are made up of MedLine abstracts (BioText, ADE,
EU-ADR, and PK), while full articles have been used only in the
ITI TXM corpora. Other corpora focus on the annotation of clinical
texts such as discharge summaries [27], patient records [20] or
clinical notes [28]. Both the PK-DDI corpus and that developed
by Rubrichi et al., consist of texts taken from drug package inserts,
which are one of the most important sources of information for
healthcare professionals and patients on the use of medicines.
Table 1 shows the size of the aforesaid corpora. As regards the
number of drug entities, the ITI TXM corpus is the largest corpora
with almost 18,000 drug compounds, followed by the PK-DDI cor-
pus. The PK-DDI corpus was annotated with a total of 3551 active
ingredients, 234 drug products and 201 metabolites. Only the PK
and PK-DDI corpus contain DDIs. The size of the different corpora
of MedLine abstracts never exceeds 500 abstracts.
Although almost all of the aforementioned corpora were cre-
ated in accordance with a set of guidelines, only a small number
of corpora have published their guidelines. Similarly, only some
corpora provide inter-annotator agreement scores. In general, the
consistency in the annotation of drug entities is high (greater than
75%), while IAA scores reported in the PK-DDI corpus (around 60%)
suggest that annotation of DDIs is a more complex task than simply
the identiﬁcation of drug names.
3. Methods
A previous version of the DDI corpus was created for the DDIEx-
traction 2011 challenge [29]. The goal of this task was to promote
research and provide a common framework for comparing the lat-
est advances in Information Extraction techniques applied to the
extraction of DDIs from biomedical texts. This earlier version of
the DDI corpus consisted of 579 documents describing drug inter-
actions that were taken from the DrugBank database. The docu-
ments were parsed using the Uniﬁed Medical Language System
(UMLS) MetaMap Transfer tool (MMTx) [30] to automatically rec-
ognize drugs. Then, a pharmacist manually annotated the DDIs in
texts. The main limitations of this previous version were (1) drugs
were automatically annotated without any manual intervention in
the process, (2) no guidelines were produced, (3) the annotation
was carried out by a single annotator, and (4) the quality of the cor-
pus was not evaluated because the inter-agreement annotator was
not measured.
In the current new version, we have made several improve-
ments. First of all, two experts and two text miners with back-
ground in pharmacovigilance participated in the annotation task
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annotator agreement (IAA), a measure of the agreement between
annotators annotating the same recording, was measured in order
to assess the level of difﬁculty of the annotation task as well as the
quality of the corpus. Another signiﬁcant improvement was the
addition of MedLine abstracts to the DDI corpus.
3.1. Building the corpus
As pointed out in Section 3, the DDI corpus is made up of texts
from two different sources: documents describing DDIs from the
DrugBank database (DDI-DrugBank corpus) and MedLine abstracts
(DDI-MedLine corpus). The size of the previous version of the DDI
corpus was increased with 213 new texts from DrugBank (which
are added to the 579 existing documents) and with 233 MedLine
abstracts. Therefore, the whole DDI corpus consists of 1,025 docu-
ments. A detailed description of the method used to collect the
documents for the DDI-DrugBank corpus can be found in [19]. Doc-
ument selection for the DDI-MedLine corpus was carried out
against PubMed. An initial set of documents was selected from
PubMed using a query with ‘‘drug interactions’’ as Medical Subject
Headings (MeSH) Terms. This query returned 116,919 citations
(published between 1975 and 2011) of which 233 documents were
randomly selected for annotation (documents without an abstract
section were ruled out).
The MMTx [30] tool was used to analyze the documents in the
corpus both syntactically and semantically. The basic function of
this program is to map text to concepts in the UMLS Metathesau-
rus. This mapping between texts and UMLS concepts enables enti-
ties to be pre-annotated automatically. A more detailed description
of this process can be found in [29].
The DDI corpus is distributed in XML documents following the
format proposed by Pyysalo et al. [31], in order to unify the differ-
ent formats of the main corpora for protein–protein interaction
extraction. Our main goal is to guarantee high corpus usage and
to encourage groups studying PPI extraction to adapt their systems
to the problem of DDI extraction. This shared format follows the
standoff annotation principle in which the original sentence text
is preserved and all entities are stored as offsets (see Fig. 1).
3.2. Annotation guidelines
Our annotation guidelines provide clear and accurate deﬁni-
tions for all those entities and relationships described in the anno-
tation schema (see the Graphical Abstract). This document also
contains the rules and conventions on how the annotation task
should be carried out as well as providing examples clarifying their
use. Moreover, during the annotation process different linguistic
phenomena affecting the annotation of drug names arose. Also
the annotation of relationships between these drugs was affected
by syntactic aspects. All of them are collected in the annotation
guidelines and have been reviewed in [32].
Four entity types were proposed to annotate pharmacological
substances: drug, brand, group and drug_n. The drug type is used
to annotate those human medicines known by a generic name,Fig. 1. A fragment from twhereas those drugs described by a trade or brand name are anno-
tated as brand entities. A drug medication frequently has several
brand names since different companies can market it. The use of
a brand-name drug instead of its generic name may be related to
a higher risk of adverse drug events [33,34]. The use of either gen-
eric or brand names depends on the drug information source. Thus,
while generic names are used in medical and pharmacological
textbooks as well as scientiﬁc medical journals, brand names are
to be used in drug product labels.
Since the descriptions of DDIs involving groups of drugs are
very common in texts, our annotators decided to include the group
type to annotate groups of drugs. Extrapolating from drug interac-
tions involving a speciﬁc compound to interactions involving its
group is a common procedure in some DDI information sources.
However some authors have established that this procedure is
wrong because this generalization is not true for all drugs
[35,36]. The last entity type, drug_n, refers to those active sub-
stances not approved for human use, such as, and among others,
toxins or pesticides. This type was included because interactions
between drugs and substances not approved for human use are fre-
quently reported in Medline documents.
As regards the relationships, four different types of DDI rela-
tionships are proposed:
 mechanism: This type is used to annotate DDIs that are
described by their PK mechanism (e.g. Grepaﬂoxacin may inhibit
the metabolism of theobromine).
 effect: This type is used to annotate DDIs describing an effect
(e.g. In uninfected volunteers, 46% developed rash while receiving
SUSTIVA and clarithromycin) or a PD mechanism (e.g. Chlorthali-
done may potentiate the action of other antihypertensive drugs).
 advice: This type is used when a recommendation or advice
regarding a drug interaction is given (e.g. UROXATRAL should
not be used in combination with other alpha-blockers).
 int: This type is used when a DDI appears in the text without
providing any additional information (e.g. The interaction of
omeprazole and ketoconazole has been established).
Figs. 2 and 3 show sentences describing DDIs. In Fig. 2, the ﬁrst
sentence describes two interactions: effect and mechanism, and
the last one also describes a DDI of effect type. In Fig. 3, DDIs of ef-
fect type are described between fenﬂuramine and a group of drugs,
antihypertensive drugs, as well as with some of its members (gua-
nethidine, methyldopa, reserpine). The last sentence gives an advice
to avoid a DDI.
The proposed classiﬁcation of DDIs is consistent with the infor-
mation requirements established by pharmacology experts for an
appropriate management of DDIs in the clinical setting [35,36].
For this purpose, healthcare professionals must be provided with
information on how the interaction occurs (mechanism), what
consequences can be expected (effect) and how it can be managed
to avoid or reduce the associated risk (advice).
Furthermore, this classiﬁcation is useful to reﬂect the type of
information provided from different sources. Thus, drug product
labels provide little advice on how to minimize the risk of anhe annotated corpus.
Fig. 2. Examples of DDIs: effect and mechanism.
Fig. 3. Examples of DDIs: effect and advice.
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documents [35]. On the other hand, DDI compendia (such as
Stockley’s drug interactions [6] or Drug Interaction Facts [7]) also
contain considerable information on advice regarding drug
interactions.
In summary, the annotation guidelines provide detailed deﬁni-
tions and examples of what substances and interactions should be
annotated and which ones should not. For example metabolites
and excipients should be annotated as drug_n entities, while
drug-protein interactions or endogenous substances should not
be included in the annotation. Additionally the annotation guide-
lines contain rules to deal with the annotation of speciﬁc linguistic
phenomena such as discontinuous names, abbreviations, nested
named entities, synonyms, adjectives, hypernymic propositions,
and interacting entities. The annotation guidelines can be found
at: http://labda.inf.uc3m.es/ddicorpus.Table 2
Numbers of the annotated entities in the DDI corpus.
DDI-DrugBank DDI-MedLine Total
DRUG 9901 (63%) 1745 (63%) 11,646 (63%)
BRAND 1824 (12%) 42 (1.5%) 1866 (10%)
GROUP 3901 (25%) 324 (12%) 4225 (23%)
DRUG_N 130 (1%) 635 (23%) 765 (4%)
TOTAL 15,756 2746 18,5023.3. Annotating the corpus
This section describes the process followed in the annotation of
drugs and their interactions in the DDI corpus. Two expert pharma-
cists with a substantial background in Pharmacovigilance carried
out the annotation task. The ﬁrst contributed to the creation of
annotation guidelines and marked up the whole corpus, while
the second annotated a total of 1600 randomly selected sentences
from the DDI-DrugBank corpus and 400 ones from the DDI-Med-
Line corpus. A text miner with background in pharmacovigilance
assisted annotators in technical aspects, such as the use of the
annotation tool, and participated in the harmonization process,
giving advice to resolve conﬂicting annotations between the two
annotators after the annotation process. XML Notepad was the
annotation tool used in the process. As explained in Section 3.1,
all documents were pre-annotated with pharmacological sub-
stance entities by the MetaMap tool (all entities were annotated
with drug type). Then, the annotators manually reviewed these la-
bels and added new ones and removed and modiﬁed (in particular
the type of entity) when necessary. All mentions of pharmacolog-
ical substances were annotated (even those that were not involved
in a DDI). Finally, DDIs were manually annotated at a sentence
level.
The annotation process relied on annotation guidelines. They
were created in an iterative process. In their earliest development
stage, the ﬁrst annotator studied and annotated a set of 30 docu-
ments from DrugBank and 10 Medline abstracts. The previously
deﬁned annotation schema and initial annotation guidelines were
discussed and established by a multidisciplinary team with two
text mining experts and two pharmacists. The text mining expertschecked and reviewed those sentences containing disagreements,
which were classiﬁed according to the main reason for discrepancy
(e.g. missed entity annotation, partial matching, different entity
type assigned, missed DDI annotation, different DDI type assigned).
These cases were studied and discussed between the two annota-
tors and the two text mining experts, who helped to achieve con-
sensus on the ﬁnal corpus. Changes in the corpus were made
accordingly to the consensus-driven decisions. On the same way,
annotation guidelines were modiﬁed to include new rules and
examples.
3.4. Inter-annotator agreement
To assess the consistency and quality of the corpus as well as
the complexity of the annotation task, the inter-annotator agree-
ment was measured in terms of the standard Kappa statistic [37].
From each dataset, DDI-DrugBank and DDI-MedLine, a set of docu-
ments was randomly selected and annotated by two different
annotators. We should note that the IAA scores were measured
after a rigorous process to deﬁne strict, comprehensive and clear
guidelines. For this reason, IAA scores were calculated under exact
match criteria, that is, the annotations should overlap completely.
For the entities, their annotations should overlap completely and
annotators should also agree on the assigned types. As regards
the interactions, the annotators should agree in the annotation of
the interacting drugs as well as the type assigned to the interac-
tion. IAA results are shown in the following section.
4. Results
Based on the sentence splitting during preprocessing, the DDI-
DrugBank corpus contains 6795 sentences, and the DDI-MedLine
corpus is made up of 2147 sentences. Table 2 shows the number
of the named entity types annotated in each corpus. The most com-
mon type was drug (63%) in both corpora. However, the numbers
of other types of entity differ between both sub-corpora. For exam-
ple, while the second most common type in the DDI-MedLine cor-
pus was drug-n (23%), these substances hardly ever occur in the
Table 3
Numbers of the annotated relationships in each corpus.
DDI-DrugBank DDI-MedLine Total
EFFECT 1855 (39.4%) 214 (65.4%) 2069 (41.1%)
MECHANISM 1,539 (32.7%) 86 (26.3%) 1625 (32.3%)
ADVICE 1035 (22%) 15 (4.6%) 1050 (20.9%)
INT 272 (5.8%) 12 (3.7%) 284 (5.6%)
TOTAL 4701 327 5028
Table 5
IAA results of the annotated relationships in the DDI corpus.
DDI-DrugBank DDI-MedLine
KEFFECT 0.7525 0.5548
KMECHANISM 0.4214 0.5577
KADVICE 0.9428 0.5587
KINT 0.9558 0.7252
K 0.8385 0.6213
918 M. Herrero-Zazo et al. / Journal of Biomedical Informatics 46 (2013) 914–920DDI-DrugBank corpus. As regards relationships, Table 3 shows the
numbers of the annotated relationships in each corpus. Effect was
the dominant relationship found in the whole DDI corpus. Advice,
accounting for 20.9% of the whole relationship, showed an even
greater disproportion between both corpora because the ratio of
relationship being advice interactions in the DDI-DrugBank corpus
(22%) is much higher than in the DDI-Medline corpus (5%). These
results are further discussed in the next section.
Table 4 presents the results for the agreement per type of entity.
For the DDI-DrugBank corpus, IAA results show very high agree-
ment (0.95) for drug, brand and group entities compared to mod-
erate agreement for drug-n entities (0.44). For the DDI-MedLine
corpus, all types of entities show close and good IAA scores. In gen-
eral, IAA was higher for the DDI-DrugBank corpus than for the DDI-
MedLine corpus, except for the drug-n entity that exhibits greater
IAA in the DDI-MedLine corpus. The overall k per type of interac-
tion (see Table 5) is greater for the DDI-DrugBank corpus
(0.8385) than for the DDI-MedLine corpus (0.6213). The int type
exhibits the highest IAA in both corpora. While in the DDI-MedLine
corpus, the other types (effect, mechanism and advice) show very
close scores to each other (0.55), in the DDI-DrugBank corpus, the
mechanism type shows a lower agreement than the other types.
These results are further discussed in the next section.5. Discussion
Recently, there have been several attempts to build annotated
corpora of DDIs [24,26]. These corpora vary in size, type of annota-
tion and type of document.
The size of the DDI corpus is signiﬁcantly larger than that of
other corpora annotated with drugs and DDIs, both in the number
of documents, as well as in the total number of annotated entities
and relationships.
The DDI corpus is made up of two different types of text: Med-
Line abstracts and documents describing DDIs from the DrugBank
database. Thus, the corpus covers two different styles of biomedi-
cal text: while the texts taken from the DrugBank database are
completely focused on the description of DDIs, the main topic of
the scientiﬁc texts would not necessarily be on DDIs. Moreover,
while abstracts are usually written in a very scientiﬁc language,
the language used in the texts from DrugBank is similar to the lan-
guage used in package inserts.
Our annotation guidelines could serve as a standard for anno-
tating drug names. Further, it is important to note that the DDI cor-
pus is the only available corpus speciﬁcally annotated with groupsTable 4
IAA results of the annotated entities in the DDI corpus.
DDI-DrugBank DDI-MedLine
KDRUG 0.9534 0.8467
KBRAND 0.9569 0.8853
KGROUP 0.9563 0.8299
KDRUG_n 0.4422 0.8122
K 0.9104 0.7962of drugs and substances not approved for human use. The PK and of
DDIs occurring through a PK mechanism. According to the authors
of the PK-DDI corpus, the vocabulary used to describe this type of
DDIs is signiﬁcantly different from that used to describe PD DDIs
because they are discovered in distinct ways. In contrast to these
previous corpora, the DDI corpus is annotated with all DDIs de-
scribed in its texts, including both PK and PD DDIs. Additionally,
the proposed classiﬁcation of DDIs is based on the information
requirements for the effective management of DDIs.
The different nature of the texts determines that the types of
entity and relationship have different ratios in the two subcorpora.
For example, substances not approved for human use are the sec-
ond most common type of entity in DDI-MedLine, these substances
account for only about 1 percent of the entities in the DDI-Drug-
Bank corpus. Similarly, brand drugs are about 12% of the entities
in the DDI-DrugBank corpus; however this type had the lowest fre-
quency in the DDI-MedLine corpus. These observations make sense
because MedLine abstracts usually describe results from laboratory
experiments, while DrugBank texts are mainly compiled from
repositories of drug interactions. As regards the distribution of
the relationships, the main difference between two subcorpora is
that the advice relationship is far more frequent in DDI-DrugBank
than in DDI-MedLine corpus. This is also consistent with the fact
that the texts from DrugBank seem to be aimed at health-care pro-
fessionals because these texts usually contain recommendations to
avoid any drug interactions and their side effects.
The most common type of relationship in the corpus is effect.
Thus, this corpus is annotated with a large amount of information
describing PD mechanisms and interaction effects. At the same
time, the corpus contains a lot of information on PK DDIs. However,
both DrugBank and MedLine documents in the corpus present a
low frequency of management recommendations. These results
agree with the characteristics of the main DDI information sources
[35,36].
Both the quality and consistency of the corpus were evaluated
by measuring the IAA scores, which allow the complexity of the
annotation task to be determined as well as providing insights into
the quality of the guidelines developed. Moreover, IAA also pro-
vides an upper bound on the performance of the automatic sys-
tems for the detection of pharmacological substances and the
interactions between them.
As regards the type of source, IAA was higher for the DDI-
DrugBank corpus than for the DDI-MedLine corpus in both entities
and relationships. One explanation for this is that MedLine
abstracts have far more complexity than texts from the DrugBank
database, which are usually expressed in simple sentences.
Similar to other annotated corpora [22,2], IAA scores are higher
for entities than for relationships. As regards the type of entity, the
highest IAA score is obtained for the brand type in both DDI-
DrugBank and DDI-MedLine corpora (see Table 4). This may be
because branded drug names are carefully selected by the manu-
facturer to be short, unique and easy to remember [38]. A high
level of agreement is observed for drugs and groups. High IAA
scores may indicate that these types are more clearly deﬁned than
others in the annotation guidelines [39]. For example, our annota-
tors found the identiﬁcation of experimental drugs (e.g. pempidine),
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identiﬁcation of the names referring to approved drugs or groups
of drugs.
On the other hand, IAA results show moderate agreement for
drug_n entities. These results can be due to the large variety of
substances included in this type. Additionally, since some of these
substances can be both endogenous (produced inside an organism)
and exogenous (produced outside the body) (e.g. calcium or dopa-
mine), their recognition depends substantially on the context in
which they appear. We should comment that the mentions of
endogenous substances should not be annotated as pharmacologi-
cal substances. In particular, the agreement was lower for drug_n
in the DrugBank corpus than in the DDI-MedLine. Metabolite
names (e.g. descarboethoxyloratadine), which are very similar to
drug names (e.g. loratadine), are very frequent in DrugBank texts.
Annotators often have difﬁculty distinguishing between both
types. Similarly another main reason for disagreement between
annotators was the classiﬁcation of substances such as vitamins
since some of them can be considered as group of drugs (e.g. vita-
min A) while others are drugs (e.g. betacarotene). These differences
were resolved in the harmonization process and more accurate
explanations were included in the annotation guidelines.
In conclusion, the IAA scores show that annotation guidelines
have been successfully developed and validated for the annotation
of complex drug names such as stereoisomer (e.g. S-warfarin), salts
(e.g. oxycodone hydrochloride) or nested named terms (e.g., thiazide
diuretics). Therefore, the DDI corpus may be a valuable resource for
developing systems for pharmacological substance recognition.
In general terms, fairly high IAA results are obtained per type of
interaction (see Table 5). The int type presents the highest IAA
scores in both DDI-DrugBank and DDI-Medline datasets. However,
this is the lowest common type of relationship (less than 6%) anno-
tated in the corpus (see Table 3). The second DDI relationship with
higher IAA results is the advice type. This type of DDI information
is very clear and can be easily identiﬁed by manual annotators in
both types of document. On the other hand, two main reasons
for disagreement in DDI type advice have been observed. Firstly,
annotators are frequently confused with sentences containing a
recommendation for a speciﬁc DDI effect, as in the following sen-
tence:‘Consider additive sedative effects and confusional states to
emerge if chlorprothixene is given with benzodiazepines or barbitu-
rates’. Similarly annotators also had problems with sentences
describing a PK mechanism and suggesting a posology change to
avoid undesired consequences. For example, the sentence: ‘Fenoﬁ-
brate should be taken at least 1 h before or 4–6 h after a bile acid bind-
ing resin to avoid impeding its absorption’ was considered as advice
by one annotator while the another one classiﬁed it as mechanism.
As shown in Table 5, the mechanism type shows the lowest IAA
scores in DDI-DrugBank corpus. One reason for this result is that
annotators ﬁnd it difﬁcult to distinguish between sentences
describing a PD mechanism or an effect. This observation led to
the ﬁnal annotation of PD interactions with the effect type.
In general, some disagreements may be because many sen-
tences provide various textual evidence of the same interaction
and each piece of textual evidence may correspond to a different
type of drug interaction. This is very common in complex sen-
tences because subordinate clauses often describe different prop-
erties of the same interaction. In these cases, the guidelines have
proposed a priority rule to assign the type of interaction (see the
guidelines section). However, sometimes the annotators incor-
rectly applied this rule, and they often tended to assign the ﬁrst
type described in the sentence instead of the type according to
the priority rule. On the other hand, the guidelines state that
clauses in compound sentences should be considered as indepen-
dent sentences, and thereby, annotators should annotate each of
drug interactions described in their clauses.6. Conclusion
We describe our efforts to build a manually annotated corpus
for DDIs in biomedical texts. To the best of our knowledge, the
problem of producing an annotated corpus for DDI extraction has
not been explored to the depth and extent reported in this work,
and the resulting corpus is the most richly semantically annotated
resource for pharmacological text processing built to date. The DDI
corpus can encourage the NLP community to research the develop-
ment of automatic tools to support to healthcare professionals in
the early detection of DDIs.
To ensure the quality of the corpus and the consistency of the
annotation, we decided to focus in the ﬁne-grained annotation de-
scribed in this paper. In view of the preliminary results obtained in
the SemEval 2013 DDI Extraction Task, the main objective of our
work, the creation of a gold standard for the recognition and clas-
siﬁcation of different drug names and their interactions, has been
achieved. Once this stage has been reached, a signiﬁcant challenge
for future work is the annotation of relevant features such as drug
dosages, time interval between administration of the drugs, and
the mechanism and effect of an interaction. These features would
be very useful to characterize the previously identiﬁed drug inter-
actions. In the future, we would also like to increase the size of the
corpus using other textual sources such as package inserts, patient
records, case studies, discharge summaries, among others. Addi-
tionally we will annotate the interactions at document level for
capturing those interactions spanning several sentences.
The resources described in this work, including both the anno-
tated corpus and the annotation guidelines, are available from
http://labda.inf.uc3m.es/ddicorpus.Acknowledgments
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